Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text

Bausch Health Companies Inc.

Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.
Trial evaluated primary prevention of hepatic encephalopathy; specific endpoint outcomes not provided in filing summary.
Filing includes only the 8-K body; the attached Exhibit 99.1 text was not included for analysis.
Item 7.01 Regulation FD disclosure; information is furnished, not filed, per standard practice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.